Home
EDIT
EDIT News

Latest Editas Medicine Inc. (EDIT) News on February 23, 2025

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

2 days ago

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Editas Medicine Outlines 2025 Strategic Priorities and Milestones

TipRanks

a month ago

Editas Medicine Outlines 2025 Strategic Priorities and Milestones

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Zacks

a month ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

GlobeNewswire

a month ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Zacks

a month ago

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

2 months ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

Insider Monkey

2 months ago

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Zacks

2 months ago

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

MT Newswires

2 months ago

JPMorgan Downgrades Editas Medicine to Underweight From Neutral

Editas Medicine price target lowered to $8 from $10 at Baird

TipRanks

2 months ago

Editas Medicine price target lowered to $8 from $10 at Baird

Investing.com

2 months ago

Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%

Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts

GuruFocus.com

2 months ago

Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts

MT Newswires

2 months ago

JonesTrading Downgrades Editas Medicine to Hold From Buy

MT Newswires

2 months ago

Stifel Downgrades Editas Medicine Hold From Buy, Adjusts Price Target to 3 From $11

MT Newswires

2 months ago

Truist Securities Downgrades Editas Medicine Hold From Buy

MT Newswires

2 months ago

RBC Cuts Price Target on Editas Medicine to $4 From $5, Keeps Sector Perform, Speculative Risk

MT Newswires

2 months ago

Truist Downgrades Editas Medicine to Hold From Buy, Removes $8 Price Target

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Benzinga

2 months ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

MT Newswires

2 months ago

Editas Medicine Focuses on In Vivo Gene-Editing Medicines, Ends Reni-Cel Development to Cut Costs

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

GlobeNewswire

2 months ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Editas to lay off staff after search for sickle cell partner comes up empty

BioPharma Dive

2 months ago

Editas to lay off staff after search for sickle cell partner comes up empty

MT Newswires

2 months ago

Wells Fargo Downgrades Editas Medicine to Equal Weight From Overweight, Cuts Price Target to $4 From $7

Editas Stock Rises on Updated Data From SCD Study of Reni-Cel

Zacks

2 months ago

Editas Stock Rises on Updated Data From SCD Study of Reni-Cel

MT Newswires

2 months ago

Editas Medicine Shares Jump as Potential Gene Therapy for Sickle Cell Disease Found to Be 'Well-Tolerated'

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

GlobeNewswire

2 months ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

Zacks

3 months ago

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

Editas Medicine downgraded to Underperform from Buy at BofA

TipRanks

3 months ago

Editas Medicine downgraded to Underperform from Buy at BofA

MT Newswires

3 months ago

BofA Securities Downgrades Editas Medicine to Underperform

Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire

4 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19%

Simply Wall St.

4 months ago

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19%

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty

GuruFocus.com

4 months ago

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y

Zacks

4 months ago

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks

4 months ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

4 months ago

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations

MT Newswires

4 months ago

Raymond James Downgrades Editas Medicine to Market Perform From Outperform

MT Newswires

4 months ago

Truist Securities Adjusts Editas Medicine's Price Target to $8 From $12, Keeps Buy Rating

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

Zacks

4 months ago

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

Associated Press Finance

4 months ago

Editas: Q3 Earnings Snapshot

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

GlobeNewswire

4 months ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?

Insider Monkey

4 months ago

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for

Zacks

4 months ago

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline

Zacks

4 months ago

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

Zacks

4 months ago

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

Zacks

4 months ago

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

MT Newswires

4 months ago

Chardan Cuts Price Target on Editas Medicine to $12 From $20, Keeps Buy Rating

Editas and Genevant team up to develop gene editing therapies

Pharmaceutical Technology

4 months ago

Editas and Genevant team up to develop gene editing therapies

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies

Zacks

4 months ago

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies

MT Newswires

4 months ago

Editas Medicine Achieves Proof of Concept for In Vivo Gene Editing of Hematopoietic Stem Cells in Humanized Mice

Editas, changing course again, looks to partner lead CRISPR therapy

BioPharma Dive

4 months ago

Editas, changing course again, looks to partner lead CRISPR therapy

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

GlobeNewswire

4 months ago

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

MT Newswires

4 months ago

Editas Medicine, Genevant Partner to Develop mRNA-LNP Gene Editing Therapeutics

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

GlobeNewswire

4 months ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

GlobeNewswire

4 months ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

State Street Corp's Strategic Reduction in Editas Medicine Inc Holdings

GuruFocus.com

4 months ago

State Street Corp's Strategic Reduction in Editas Medicine Inc Holdings

Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 64% of the company

Simply Wall St.

4 months ago

Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 64% of the company

Editas Medicine Secures $57M Deal for Gene-Editing Technology

TipRanks

5 months ago

Editas Medicine Secures $57M Deal for Gene-Editing Technology

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

Pharmaceutical Technology

5 months ago

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

MT Newswires

5 months ago

National Bank on DRI Healthcare's Casgevy Stream Acquisition

Editas trades Vertex fees for upfront cash in DRI deal

BioPharma Dive

5 months ago

Editas trades Vertex fees for upfront cash in DRI deal

MT Newswires

5 months ago

DRI Healthcare Trust Buying Payment Streams Based On Gene-Editing Technology For US$57 Million

MT Newswires

5 months ago

Editas Medicine Sells Future License Fees for Gene-Editing Technology for $57 Million

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

GlobeNewswire

5 months ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

MT Newswires

5 months ago

JonesTrading Initiates Editas Medicine at Buy With $13 Price Target

Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?

Zacks

6 months ago

Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?

Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire

6 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

We're Keeping An Eye On Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

Simply Wall St.

6 months ago

We're Keeping An Eye On Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down

Zacks

6 months ago

Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down

MT Newswires

6 months ago

BofA Securities Upgrades Editas Medicine to Buy From Neutral

MT Newswires

6 months ago

Truist Securities Adjusts Price Target on Editas Medicine to $12 From $20, Maintains Buy Rating

Thomson Reuters StreetEvents

6 months ago

Q2 2024 Editas Medicine Inc Earnings Call

Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates

Zacks

7 months ago

Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates

Associated Press Finance

7 months ago

Editas: Q2 Earnings Snapshot

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

GlobeNewswire

7 months ago

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

GlobeNewswire

7 months ago

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

MT Newswires

7 months ago

RBC Cuts Price Target on Editas Medicine to $8 From $11, Keeps Sector Perform, Speculative Risk

Editas Medicine (NASDAQ:EDIT) investors are sitting on a loss of 90% if they invested three years ago

Simply Wall St.

8 months ago

Editas Medicine (NASDAQ:EDIT) investors are sitting on a loss of 90% if they invested three years ago

Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now?

Insider Monkey

8 months ago

Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now?

What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential?

Insider Monkey

8 months ago

What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential?

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

Zacks

8 months ago

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

MT Newswires

8 months ago

Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

GlobeNewswire

8 months ago

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

GlobeNewswire

8 months ago

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

Lotto 6/49 - $64 million up for grabs in the next draw!

CNW Group

8 months ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

8 months ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

8 months ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

8 months ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

8 months ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

8 months ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

8 months ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

8 months ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses

Investor's Business Daily

8 months ago

IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses

Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library

Business Wire

8 months ago

Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library

Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap

Investor's Business Daily

8 months ago

Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap

EnviroGold Global Closes First Tranche of Private Placement

GlobeNewswire

8 months ago

EnviroGold Global Closes First Tranche of Private Placement

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

GuruFocus.com

8 months ago

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

How markets digested hot jobs print: Top takeaways

Yahoo Finance Video

8 months ago

How markets digested hot jobs print: Top takeaways

SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"

PR Newswire

8 months ago

SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswire

8 months ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?

Zacks

8 months ago

Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?

MT Newswires

9 months ago

Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating

Share on Social Networks: